Immuron Stock

Immuron Net Income

The Net Income of Immuron (IMC.AX) as of Aug 23, 2026 is -5.22 M AUD. In the previous year, Net Income was -6.94 M AUD — a change of -24.81% (higher).

Net Income

-5.22 MAUD

YoY

-24.81%

Last updated:

In 2026, Immuron's profit amounted to -5.22 M AUD, a -24.81% increase from the -6.94 M AUD profit recorded in the previous year.

The Immuron Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2018
-3.01 M AUD
Jan 1, 2019
-4.66 M AUD
Jan 1, 2020
-2.93 M AUD
Jan 1, 2021
-8.38 M AUD
Jan 1, 2022
-2.85 M AUD
Jan 1, 2023
-3.79 M AUD
Jan 1, 2024
-6.94 M AUD
Jan 1, 2025
-5.22 M AUD
The Immuron Net Income history
YEARNet IncomeYoY
-5.22 MAUD-24.81%
-6.94 MAUD+83.20%
-3.79 MAUD+32.66%
-2.85 MAUD-65.96%
-8.38 MAUD+186.43%
-2.93 MAUD-37.14%
-4.66 MAUD+54.65%
-3.01 MAUD-55.75%
-6.80 MAUD+21.53%
-5.60 MAUD+62.38%
-3.45 MAUD+35.75%
-2.54 MAUD-28.25%
-3.54 MAUD+53.91%
-2.30 MAUD-11.54%
-2.60 MAUD+36.84%
-1.90 MAUD-18.10%
-2.32 MAUD-18.88%
-2.86 MAUD-12.80%
-3.28 MAUD-7.87%
-3.56 MAUD
Access this data via the Eulerpool API

Immuron Revenue

Immuron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
3.69 M AUD
-2.83 M AUD
-3.01 M AUD
Jan 1, 2019
2.39 M AUD
-4.69 M AUD
-4.66 M AUD
Jan 1, 2020
2.52 M AUD
-3.07 M AUD
-2.93 M AUD
Jan 1, 2021
145,800.00 AUD
-7.20 M AUD
-8.38 M AUD
Jan 1, 2022
765,200.00 AUD
-3.12 M AUD
-2.85 M AUD
Jan 1, 2023
1.80 M AUD
-3.44 M AUD
-3.79 M AUD
Jan 1, 2024
4.90 M AUD
-5.24 M AUD
-6.94 M AUD
Jan 1, 2025
7.29 M AUD
-5.36 M AUD
-5.22 M AUD

Immuron Margins

Immuron stock margins

The Immuron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immuron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immuron.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
88.66 %
-76.58 %
-81.52 %
Jan 1, 2019
72.05 %
-196.65 %
-195.04 %
Jan 1, 2020
72.65 %
-121.96 %
-116.22 %
Jan 1, 2021
64.95 %
-4,937.72 %
-5,750.69 %
Jan 1, 2022
68.41 %
-407.40 %
-373.01 %
Jan 1, 2023
96.42 %
-190.44 %
-209.81 %
Jan 1, 2024
68.06 %
-106.95 %
-141.49 %
Jan 1, 2025
65.39 %
-73.51 %
-71.58 %

Immuron Stock analysis

What does Immuron do? Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Immuron's Profit Margins

The profit margins of Immuron represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Immuron's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Immuron's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Immuron's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Immuron’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Immuron stock

Net Income of Immuron is -5.22 M AUD in 2026.

Net Income of Immuron changed from -6.94 M AUD to -5.22 M AUD, representing a -24.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Immuron since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Immuron historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

Income Statement — Immuron

All Key Metrics — Immuron